Clinical Trial

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

Study acronym: emvigorate
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emvigorate
Protocol Amendment History 2 changes
notable Trial sites expanded: 75 -> 82 locations 2026-07-22
notable Trial sites expanded: 47 -> 73 locations 2026-05-09
Trial Details
NCT Number NCT06920004
Lead Sponsor argenx
Conditions Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Enrollment 218 participants
Start Date 2025-08-22
Primary Completion 2027-09 (estimated)
Study Completion 2030-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-21